Eribulina Advanz Pharma

Eribulin Mesylate is a chemotherapy drug used to treat certain types of cancer. It works by slowing or stopping cancer cell growth, often prescribed for metastatic breast cancer.

Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer. It may also be considered for other types of cancer under medical supervision. The drug is administered intravenously and targets cancer cells to inhibit their growth.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects vary among individuals and should be discussed with a healthcare provider.

Eribulin Mesylate should be handled with care, as it is a potent chemotherapy agent. It is important to follow proper safety protocols when administering the drug to avoid contamination. Patients should be monitored for signs of infection or other complications during treatment.

Eribulin Mesylate may interact with other medications, including those that affect liver function. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol consumption should be avoided during treatment.